资讯

Clinical Trials Arena12 小时
ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data
ADC Therapeutics has pulled the drug candidate from development, leaving it with one remaining clinical asset.
Clinical Trials Arena14 小时
Nuvig Therapeutics begins dosing in trial of NVG-2089 for CIDP
Nuvig Therapeutics has dosed the first subject in its Phase II INVGOR trial of NVG-2089 for individuals with CIDP.
clinicaltrialsarena23 小时
First subject dosed in Revolution Medicines’ Phase III NSCLC treatment trial
The trial aims to enrol roughly 420 NSCLC subjects who have undergone one to two previous therapy lines for advanced disease. Credit: create jobs 51/Shutterstock. Revolution Medicines has dosed the ...